Summit Therapeutics shares surge after-hours following $2 billion AstraZeneca equity investment

Source Summary

Summit Therapeutics' shares rose in after-hours trading following an announcement of a $2 billion equity deal with AstraZeneca. The investment represents a significant capital infusion for the biotech company.

Why it matters

The $2 billion equity investment from a major pharmaceutical company signals confidence in Summit's pipeline and provides substantial capital for development and operations.

Read the Source

Investing.com ↗

NASDAQ:SMMTLive chart

Trading trends

The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.

Recent SEC-reported share and derivative transactions in Summit Therapeutics Inc..

Insider activity sentiment

Neutral

BearishNeutralBullish

0 discretionary purchases · 0 discretionary sales

Confidence: Low

Informative buyNon-informative buyInformative sellNon-informative sell

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
Co-Chief Executive OfficerZanganeh Mahkam	Informative buy	Common StockOpen-market or private transaction (P)	3,810,000	$13.12	$49,987,200	Jun 12, 2026
Co-Chief Executive OfficerDUGGAN ROBERT W	Informative buy	Common StockOpen-market or private transaction (P)	3,810,000	$13.12	$49,987,200	Jun 12, 2026
Co-Chief Executive OfficerDUGGAN ROBERT W	Informative buy	Common StockOpen-market or private transaction (P)	100,000	$14.60	$1,460,000	Jun 4, 2026
Co-Chief Executive OfficerZanganeh Mahkam	Informative buy	Common StockOpen-market or private transaction (P)	100,000	$14.60	$1,460,000	Jun 4, 2026
COO and CFOSoni Manmeet Singh	Informative buy	Common StockOpen-market or private transaction (P)	25,000	$14.46	$361,500	Jun 4, 2026

As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.

Short interest

Open short positions reported twice monthly; this is not daily short-sale volume.

Earnings

Recent reported earnings per share compared with the analyst consensus available from Nasdaq.

Comments

No published comments yet.

Owner	Activity	Change	Shares held	Value (thousands)	Reported
Baker Bros. Advisors Lp	Sell	-3,604,715 (-9.905%)	32,786,348	$511,795	6/30/2026
Vanguard Group Inc	Sell	-202,508 (-1.78%)	11,177,220	$174,476	12/31/2025
Fmr Llc	Sell	-809,252 (-7.456%)	10,043,947	$156,786	6/30/2026
State Street Corp	Buy	2,508,636 (35.694%)	9,536,796	$148,869	6/30/2026
Blackrock, Inc.	Sell	-124,717 (-1.292%)	9,529,041	$148,748	6/30/2026
Vanguard Capital Management Llc	Buy	22,682 (0.397%)	5,734,484	$89,515	6/30/2026
Ubs Group Ag	Buy	1,553,483 (42.211%)	5,233,798	$81,700	6/30/2026
Vanguard Portfolio Management Llc	Sell	-191,062 (-3.651%)	5,042,190	$78,709	6/30/2026
Goldman Sachs Group Inc	Buy	4,202,671 (1352.524%)	4,513,399	$70,454	6/30/2026
Price T Rowe Associates Inc /Md/	Sell	-4,384,039 (-52.961%)	3,893,820	$60,783	6/30/2026
Point72 Asset Management, L.P.	Buy	2,913,617 (371.547%)	3,697,803	$57,723	6/30/2026
Geode Capital Management, Llc	Buy	111,409 (3.36%)	3,427,263	$53,500	6/30/2026

Settlement date	Short interest	Avg. daily volume	Change vs. previous report	Days to cover
Sep 15, 2026	41,081,179	6,260,891	-0.60%	6.56
Aug 31, 2026	41,330,352	6,240,461	+10.41%	6.62
Aug 14, 2026	37,432,330	4,308,749	+3.27%	8.69
Jul 31, 2026	36,245,370	4,091,058	-2.90%	8.86
Jul 15, 2026	37,327,940	3,386,533	-6.34%	11.02
Jun 30, 2026	39,855,640	5,958,124	+8.27%	6.69
Jun 15, 2026	36,811,691	8,254,320	+1.90%	4.46
May 29, 2026	36,126,988	4,410,564	—	8.19

Fiscal quarter	Reported	EPS	Consensus	Surprise
Jun 2026	Jul 23, 2026	-0.28	-0.26	-7.69%
Mar 2026	Apr 30, 2026	-0.24	-0.33	+27.27%
Dec 2025	Feb 23, 2026	-0.29	-0.22	-31.82%
Sep 2025	Oct 20, 2025	-0.31	-0.14	-121.43%

Source Summary

Why it matters

Read the Source

NASDAQ:SMMT — Live chart

Insider activity sentiment

Comments

Related stories

Summit Therapeutics Surges on $2 Billion AstraZeneca Strategic Investment

Alnylam Defends Heart Disease Drugs Following AstraZeneca's Wainua Trial Failure

Roivant Shares Rise Following Mid-Stage Trial Success for Lung Disease Drug

Comments

Insider activity sentiment

NASDAQ:SMMTLive chart